Piper Sandler Initiates Coverage On Taysha Gene Therapies With Overweight Rating, Announces Price Target of $9
Piper Sandler Initiates Coverage On Taysha Gene Therapies With Overweight Rating, Announces Price Target of $9
派珀·桑德勒以增持評級啓動對Taysha基因療法的報道,宣佈目標股價爲9美元
Piper Sandler analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight rating and announces Price Target of $9.
派珀·桑德勒分析師克里斯托弗·雷蒙德以增持評級啓動了對Taysha Gene Therapies(納斯達克股票代碼:TSHA)的報道,並宣佈目標股價爲9美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。